Cartesian Therapeutics (RNAC) Invested Capital (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Invested Capital data on file, last reported at -$148.1 million in Q1 2026.

• Invested Capital for Q1 2026 came in at -$148.1 million, down 579.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$148.1 million (down 579.78% YoY), and the FY2025 annual result was -$126.2 million, down 1755.92% from the prior year.
• Invested Capital declined to -$148.1 million in Q1 2026 per RNAC's latest filing, from -$126.2 million in the prior quarter.
• Over five years, Invested Capital peaked at $93.8 million in Q4 2022 and troughed at -$411.9 million in Q4 2023.
• A 5-year average of -$24.5 million and a median of -$2.5 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital surged 4910.51% in 2022, then slumped 4866.49% in 2025.
• A 5-year view of Invested Capital shows it stood at $93.8 million in 2022, then plunged by 538.97% to -$411.9 million in 2023, then soared by 98.35% to -$6.8 million in 2024, then sank by 1755.92% to -$126.2 million in 2025, then declined by 17.33% to -$148.1 million in 2026.
• Business Quant data shows RNAC's Invested Capital at -$148.1 million in Q1 2026, -$126.2 million in Q4 2025, and -$35.8 million in Q3 2025.